These results warrant more detailed future studies with a larger number of patients and further evaluation of germline and somatic BRCA1/BRCA2 PSVs to better understand their impact on ovarian cancer patient outcomes in Gulf countries. This evidence concerns the gene BRCA2 and ovarian cancer.